Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Gurin

Urology Annals

Volumn 3, Issue 3, 2011, Pages 119-126

  Alkhateeb, Sultan S ^a   Neill, Mischel ^a   Bar Moshe, Sas ^b   Rhijn, Bas Van ^a   Kakiashvili, David M ^a   Fleshner, Neil ^a   Jewett, Michael ^a   Petein, Michel ^c   Schulman, Claude ^c   Hanna, Sally ^a   Bostrom, Peter J ^a,b   Roumeguere, Thierry ^c   Shariat, Shahrokh F ^d   Rorive, Sandrine ^c   Zlotta, Alexandre R ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ERASME HOSPITAL   (Belgium)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BCG; Bcl 2; bladder cancer; cyclinD1; EORTC; high risk; long term response; metallothionein 9; p21; p53; waf1 cip

Indexed keywords

BCG VACCINE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; METALLOTHIONEIN; METALLOTHIONEIN 9; MOLECULAR MARKER; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BCG VACCINATION; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; EORTC SCORING SYSTEM; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NONMUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL RATE; TRANSURETHRAL RESECTION;

EID: 80053077763     PISSN: 09747796     EISSN: 09747834     Source Type: Journal    
DOI: 10.4103/0974-7796.84954     Document Type: Article

References (36)

1. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000;163:73-8.
2. Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002;167:1573-83. (Pubitemid 34240678)
3. Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70.
4. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90-5. (Pubitemid 35461559)
5. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1grade 3 bladder cancer: Recurrence, progression and survival. J Urol 2003;169:96-100. (Pubitemid 35461560)
6. Brake M, Loertzer H, Horsch R, Keller H. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 2000;163:1697-701. (Pubitemid 30366716)
7. Zlotta AR, Drowart A, Huygen K, De Bruyn J, Shekarsarai H, Decock M, et al. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guerin (BCG) in patients with superficial bladder cancer. Clin Exp Immunol 1997;109:157-65. (Pubitemid 27293898)
8. Zlotta AR, Drowart A, Van Vooren JP, de Cock M, Pirson M, Palfliet K, et al. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer. J Urol 1997;157:492-8. (Pubitemid 27026824)
9. Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 2000;164:2129-33.
10. de Reijke TM, de Boer EC, Kurth KH, Schamhart DH. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: Processing, stability and prognostic value. J Urol 1996;155:477-82. (Pubitemid 26023528)
11. Zlotta AR, Noel JC, Fayt I, Drowart A, Van Vooren JP, Huygen K, et al. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J Urol 1999;161:792-8. (Pubitemid 29422368)
12. Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 2007;20:445-59. (Pubitemid 46482368)
13. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432:316-23. (Pubitemid 39551659)
14. Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, Dickinson MG, et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998;90:1072-9. (Pubitemid 28350272)
15. Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004;22:1014-24. (Pubitemid 41095033)
16. Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004;22:1007-13. (Pubitemid 41095032)
17. Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007;8:128-36. (Pubitemid 46158371)
18. Pfister C, Flaman JM, Dunet F, Grise P, Frebourg T. p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy. J Urol 1999;162:69-73. (Pubitemid 29420882)
19. Yamasaki Y, Smith C, Weisz D, van Huizen I, Xuan J, Moussa M, et al. Metallothionein expression as prognostic factor for transitional cell carcinoma of bladder. Urology 2006;67:530-5. (Pubitemid 43343536)
20. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol 2006;37:1568-76. (Pubitemid 44792223)
21. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 2007;177:481-7. (Pubitemid 46054033)
22. Sylvester RJ. Combining a molecular profile with a clinical and pathologicalprofile: biostatistical considerations. Scand J Urol Nephrol Suppl 2008;218:185-90.
23. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006:49:466-5.
24. Rodriguez-Alonso A, Pita-Fernandez S, Gonzalez-Carrero J, Nogueira-March JL. p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma. Eur Urol 2002;41:182-8.
25. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005;6:678-86. (Pubitemid 41222758)
26. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54:3391-5. (Pubitemid 24225956)
27. Zhang G, Chen F, Cao Y, See WA, Milwaukee W. P21 expression by human urothelial carcinoma cells modulates the phenotypic response to BCG. J Urol 2009;181:1155.
28. Abukhdeir AM, Park BH. P21 and p27: Roles in carcinogenesis and drug resistance. Expert Rev Mol Med 2008;10: e19.
29. Sgambato A, Migaldi M, Faraglia B, De Aloysio G, Ferrari P, Ardito R, et al. Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome. Int J Cancer 2002;97:671-8. (Pubitemid 34087809)
30. Wagner U, Suess K, Luginbuhl T, Schmid U, Ackermann D, Zellweger T, et al. Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J Pathol 1999;188:44-50. (Pubitemid 29197313)
31. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, Carrasco JC, et al. Prognostic factors in stage T1grade 3 bladder cancer survival: The role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur Urol 2004;45:606-12. (Pubitemid 38481688)
32. Kong G, Shin KY, Oh YH, Lee JJ, Park HY, Woo YN, et al. Bcl-2 and p53 expressions in invasive bladder cancers. Acta Oncol 1998;37:715-20. (Pubitemid 29066826)
33. Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI, et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol 2009;182:78-84.
34. Bryan RT, Zeegers MP, James ND, Wallace DM, Cheng KK. Biomarkers in bladder cancer. BJU Int 2009;105:608-13.
35. Riley RD, Sauerbrei W, Altman DG. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer 2009:100:1219-29.
36. McShane LM, Aamodt R, Cordon-Cardo C, Cote R, Faraggi D, Fradet Y, et al. Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res 2000;6:1854-64. (Pubitemid 30305082)